Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway

Impact · against what's priced in

The news is largely a confirmation of existing expectations for JNJ and a neutral-to-negative reminder for ISRG, offering no new catalysts to shift valuations. While JNJ's raised guidance and OTTAVA approval are positive, they are already baked into the current price, and the negative free cash flow merely validates existing risks.

ISRG−0.10

Already priced in

The price assumes

The incumbent moat protecting current market share from early-stage competition